Outlook Therapeutics, Inc. (OTLK)
|52 Week Range||0.684-2.115|
|1y Target Est||-|
|DCF Unlevered||OTLK DCF ->|
|DCF Levered||OTLK LDCF ->|
|Debt / Equity||297.80%||Strong Buy|
Upgrades & Downgrades
Latest OTLK news
Outlook Therapeutics ends 1Q with cash and equivalents of $52.3M; says it has sufficient capital int...
14 February 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) announced that it has ended its first quarter of fiscal 2023 with cash and equivalents of $52.3 million as of December 31, 2022, which the company says is expect...
Outlook Therapeutics strengthens medical affairs and commercial expertise with new appointments
19 January 2023
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced the appointments of Dr Surendra Sharma as senior vice president of medical affairs and Glen Olsheim as executive director of commercial excellence ...
Outlook Therapeutics plots course for wet AMD drug approval in year-end shareholder letter
29 December 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced financial results for its fiscal year ended September 30 and laid out plans for 2023 in an end-of-year letter. “Our fiscal year 2022 laid a solid f...
Outlook Therapeutics inks agreement with existing institutional and accredited investors for a regis...
23 December 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into securities purchase agreements with existing institutional and accredited investors for a registered direct offering priced at-the-marke...
Outlook Therapeutics announces validation of marketing authorization application by EMA for ONS-5010...
22 December 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) announced the validation of the company's Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for an investigational ophthalmic form...
Outlook Therapeutics says FDA approval for Lytenava will make huge difference for those with vision ...
4 November 2022
There's a question the CEO of Outlook Therapeutics Inc (NASDAQ:OTLK) likes to pose about why having US Food and Drug Administration (FDA)-approval will propel the company's upcoming treatment for reti...
Outlook Therapeutics encouraged by FDA acceptance of application for drug to treat retinal eye disea...
28 October 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its investigational ophthalmic formulation of bevacizumab...
Outlook Therapeutics enters into commercialization agreement with AmerisourceBergen
27 September 2022
Outlook Therapeutics Inc (NASDAQ:OTLK) said it has entered into a strategic relationship with healthcare company AmerisourceBergen in preparation for the anticipated commercial launch in the United St...
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
26 September 2022
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic f...
Outlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment Conference
7 September 2022
ISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic f...
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >